Methylation of MGMT and P16INK4A (CDKN2A)genes which are associated with breast cancer were investigated by technique of methylation-specific PCR (MSP).

Objective: In the era of personalized treatment methods when the molecular classification of the cancer which is developed on genetic basis, investigating the epigenetic status of tumor samples of patients will lead the details about diagnosis, treatment and prognosis to be valued. Method: We investigated the methylation status of promoters of P16 (CDKN2A), MGMT genes which are accepted as tumor suppressors in invasive breast cancer tissue and evaluated with the histopathologic prognostic findings and demographic informations belongs to the patient. MSP technique were recruited for epigenetic studies. Results: In this study the promoter hypermethylation status were observed at different rates; P16 (CDKN2A) gene with 43,8% of the cases, MGMT gene with 34,4% With these results when the prognostic factors of the patients were analyzed, tumor stage and age were found to be meaningless with the hypermethylation of P16 (CDKN2A), MGMT genes but found to be significant with age, P16 (CDKN2A), MGMT, tumor stage and PR positivity, ER positivity, <%30 Ki-67, E-Cadherin positivity and C-erb-B2 positivity were significant. To conclude with, MS- PCR makes this technique reliable for determination of the methylation profiles of breast cancer screening. Conclusion: It is obvious that molecular analyses are informative about the character of breast cancer. But without doubt, performing studies in large patient groups where advanced statistical analysis of combination of clustering and multivariate regression calculations, called data mining, can be applied is extremely important. So, it has to be among primary goals to form and maintain tumor biobanks which can enable fast and reliable practicing of precious studies in large groups.